Precision measurements in nuclear β ‐decay with LPCTrap
The experimental achievements and the current program with the LPCTrap device installed at the LIRAT beam line of the SPIRAL1‐GANIL facility are presented. The device is dedicated to the study of the weak interaction at low energy by means of precise measurements of the β−ν angular correlation parameter. Technical aspects as well as the main results are reviewed. The future program with new available beams is briefly discussed.
The WITCH experiment: Acquiring the first recoil ion spectrum
Abstract The standard model of the electroweak interaction describes β-decay in the well-known V–A form. Nevertheless, the most general Hamiltonian of a β-decay includes also other possible interaction types, e.g. scalar (S) and tensor (T) contributions, which are not fully ruled out yet experimentally. The WITCH experiment aims to study a possible admixture of these exotic interaction types in nuclear β-decay by a precise measurement of the shape of the recoil ion energy spectrum. The experimental set-up couples a double Penning trap system and a retardation spectrometer. The set-up is installed in ISOLDE/CERN and was recently shown to be fully operational. The current status of the experiment is presented together with the data acquired during the 2006 campaign, showing the first recoil ion energy spectrum obtained. The data taking procedure and corresponding data acquisition system are described in more detail. Several further technical improvements are briefly reviewed.
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
This study was designed to investigate the human absorption, disposition, and mass balance of 14C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of 14C-brivaracetam (150 mg, 82 μCi, or 3.03 MBq). Serial blood and complete urine and feces were collected until 144 h postdose. Expired air samples were obtained until 24 h. Brivaracetam was rapidly absorbed, with Cmax of 4 μg/ml occurring within 1.5 h of dosing. Unchanged brivaracetam amounted to 90% of the total plasma radioactivity, suggesting a modest first-pass effect. Plasma protein binding of radioactivity was low (17.5%). Urinary excretion exceeded 90% after 2 days, and the final mass balance reached 96.8% of the radioactivity in urine and 0.7% in feces. Only 8.6% of the radioactive dose was recovered in urine as unchanged brivaracetam, the remainder being identified as non–cytochrome P450 (P450)- and P450-dependent biotransformation products resulting from hydrolysis of the amide moiety (M9, 34.2%), hydroxylation of the n-propyl side chain (M1b, 15.9%), and a combination of these two pathways leading to the hydroxy acid (M4b, 15.2%). Minor amounts of taurine and glucuronic acid conjugates and other oxidized derivatives were also identified. Brivaracetam is completely absorbed, is weakly bound to plasma proteins, extensively biotransformed through several metabolic pathways, and eliminated renally.